Author(s): Abass Alavi
Year: 2004
Language: English
Pages: 253
Cover
......Page 1
Preface......Page 2
Radiation necrosis......Page 5
Diagnosis of radiation necrosis/tumor recurrence......Page 6
Prognosis......Page 10
PET imaging with alternative tracers......Page 13
Other tracers......Page 14
References......Page 15
General characteristics of l-[18F] 6-fluorodopa......Page 18
Diagnosis of Parkinson's disease......Page 21
Preclinical Parkinson's disease......Page 22
Other PET tracers for studying Parkinson's disease......Page 23
Multiple system atrophy......Page 25
Dopa-responsive dystonia......Page 26
References......Page 27
Solitary pulmonary nodules......Page 32
Conventional diagnostic approach in lung nodules......Page 33
Benign causes of fluorodeoxyglucose uptake......Page 34
Dual time point or delayed imaging for differentiating benign and malignant nodules......Page 35
Partial volume correction for accurate measurement of standardized uptake value......Page 36
Role of somatostatin scintigraphy in lung nodules......Page 37
Hilar and mediastinal lymph node staging......Page 38
Distant metastases......Page 39
Applications in radiation oncology......Page 41
New radiotracers and implications for the future......Page 42
Noninvasive imaging modalities......Page 43
Mesothelioma......Page 44
Distinguishing metabolic patterns for benign and malignant disorders......Page 46
References......Page 47
Applications of fluorodeoxyglucose-PET imaging in the detection of infection and inflammation and other benign disorders......Page 53
HIV and AIDS......Page 54
Orthopedic infections......Page 55
Fever of unknown origin......Page 58
Soft tissue infection and inflammations......Page 59
References......Page 60
Initial staging of melanoma......Page 67
Regional lymph node metastasis......Page 68
Distant metastasis......Page 69
Impact on patient management......Page 73
References......Page 76
Anatomy......Page 78
Oxygen, perfusion, and ventilation perfusion ratios......Page 79
Oxygen measurements......Page 81
Perfusion......Page 82
Ventilation-perfusion ratios......Page 84
Ventilation......Page 85
Diffusion......Page 87
References......Page 88
Hypoxia-induced changes in tumor biology......Page 90
Tumor hypoxia and clinical outcome: what is new?......Page 93
Methods to evaluate tumor hypoxia......Page 95
Polarographic electrode measurements......Page 96
Evaluating angiogenesis......Page 97
PET and hypoxia imaging......Page 98
Nitroimidazole compounds......Page 99
Alternative azomycin imaging agents......Page 101
Summary......Page 103
References......Page 104
Monitoring response to treatment in patients utilizing PET......Page 109
PET imaging and image analysis......Page 110
Lymphoma......Page 112
Gastric and esophageal carcinoma......Page 113
Breast cancer......Page 114
Lymphoma......Page 115
Other tumors......Page 117
Timing of serial PET imaging......Page 118
Imaging cell proliferation......Page 119
Radiolabeled amino acids......Page 120
Summary......Page 121
References......Page 122
Tissue optics......Page 125
Instrumentation......Page 126
Theory......Page 127
Brain imaging......Page 128
Breast imaging......Page 131
Muscle imaging......Page 132
References......Page 134
PET imaging of cellular proliferation......Page 139
Thymidine metabolism and consequences for imaging......Page 140
Thymidine analogues: preclinical studies and quantitative considerations......Page 142
Carbon-11-thymidine (TdR) imaging in patients......Page 144
Patient imaging with fluorothymidine......Page 148
Patient imaging with other thymidine analogues......Page 149
References......Page 150
Rubidium-82-labeled chloride......Page 154
Copper-62-labeled pyruvaldehyde bis (N4-methylthio-semicarbazone)......Page 155
Carbon-11-labeled palmitate and acetate......Page 156
Management of patients with left ventricular dysfunction and coronary artery disease......Page 157
Identification of myocardial viability by PET......Page 158
Predicting cardiac events, remodeling, and long-term survival......Page 159
Diagnosis of coronary artery disease......Page 160
Cardiac neuronal imaging......Page 161
References......Page 162
Patient preparation......Page 167
Epilepsy......Page 168
Cardiac applications......Page 169
Applications in oncology......Page 170
Central nervous system tumors......Page 171
Lymphoma......Page 173
Neuroblastoma......Page 175
Wilms' tumor......Page 176
Soft tissue tumors......Page 177
Summary......Page 178
References......Page 179
Interictal PET imaging......Page 185
Ictal PET imaging......Page 191
Receptor PET imaging......Page 192
Other seizure disorders......Page 193
Summary......Page 194
References......Page 195
PET imaging in the assessment of normal and impaired cognitive function......Page 199
Cerebral metabolism......Page 200
Functional development and aging......Page 202
Alzheimer's disease and other dementing illnesses......Page 203
Prognosis......Page 205
Stroke......Page 206
References......Page 207
Alzheimer's disease......Page 210
Pick's disease......Page 212
Brain tumors......Page 213
Parkinson's disease......Page 214
Cerebrovascular disease......Page 216
Head trauma......Page 218
Epilepsy and other seizure disorders......Page 219
References......Page 221
PET imaging in the assessment of normal and impaired cognitive function......Page 227
Cerebral metabolism......Page 228
Functional development and aging......Page 230
Alzheimer's disease and other dementing illnesses......Page 231
Prognosis......Page 233
Stroke......Page 234
References......Page 235
Basis of MR imaging contrast......Page 238
Basis of MR imaging contrast agents......Page 239
Gadolinium chelates......Page 240
Methods of increasing gadolinium-induced contrast......Page 241
Iron oxide nanoparticles......Page 243
MR spectroscopy......Page 247
References......Page 249
